

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

**INFORMATION DISCLOSURE
STATEMENT**

Docket Number:
10793/70

Application Number
10/611,588

Filing Date
June 30, 2003

Examiner

Art Unit
1644

Invention Title
ANTIBODIES AND USES THEREOF

Inventor(s)
LEVANON, et al.

Address to:

Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

I hereby certify that this correspondence is being deposited with the
United States Postal Service with sufficient postage as first class mail in an envelope
addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-
1450 on

Date: April 27, 2004

By:

Kathryn M. Lumb (Reg. No. 46,885)


1. In accordance with the duty of disclosure under 37 C.F.R. § 1.56 and in conformance with the procedures of 37 C.F.R. §§ 1.97 and 1.98 and M.P.E.P. § 609, attorneys for Applicants hereby bring the attached references to the attention of the Examiner. These references are listed on the attached modified PTO Form No. 1449. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.
2. The filing of this Information Disclosure Statement and the attached PTO Form No. 1449, shall not be construed as an admission that the information cited is prior art, or is considered to be material to patentability as defined in 37 C.F.R. § 1.56(b).
3. A copy of each patent, publication or other information listed on the modified PTO form 1449 is enclosed.
4. It is believed that no fees are due in connection with this Information Disclosure Statement. However, should any fees be due, the Commissioner is authorized to charge or credit any over payment to Deposit Account No. 11-0600. A duplicate copy of this communication is enclosed for charging purposes.

Dated: April 27, 2004

By:

Kathryn M. Lumb (Reg. No. 46,885)

KENYON & KENYON
One Broadway
New York, N.Y. 10004
(212) 425-7200 (Telephone)
(212) 425-5288 (Facsimile)
CUSTOMER NO. 26646



U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

**INFORMATION DISCLOSURE
STATEMENT**

Docket Number:
10793/70

Application Number
10/611,588

Filing Date
June 30, 2003

Examiner

Art Unit
1644

Invention Title
ANTIBODIES AND USES THEREOF

Inventor(s)
LEVANON, et al.


Address to:

Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

I hereby certify that this correspondence is being deposited with the
United States Postal Service with sufficient postage as first class mail in an envelope
addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-
1450 on

Date: April 27, 2004


By:


Kathryn M. Lumb (Reg. No. 46,885)


1. In accordance with the duty of disclosure under 37 C.F.R. § 1.56 and in conformance with the procedures of 37 C.F.R. §§ 1.97 and 1.98 and M.P.E.P. § 609, attorneys for Applicants hereby bring the attached references to the attention of the Examiner. These references are listed on the attached modified PTO Form No. 1449. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.
2. The filing of this Information Disclosure Statement and the attached PTO Form No. 1449, shall not be construed as an admission that the information cited is prior art, or is considered to be material to patentability as defined in 37 C.F.R. § 1.56(b).
3. A copy of each patent, publication or other information listed on the modified PTO form 1449 is enclosed.
4. It is believed that no fees are due in connection with this Information Disclosure Statement. However, should any fees be due, the Commissioner is authorized to charge or credit any over payment to Deposit Account No. 11-0600. A duplicate copy of this communication is enclosed for charging purposes.

Dated: April 27, 2004

By:


Kathryn M. Lumb (Reg. No. 46,885)

KENYON & KENYON
One Broadway
New York, N.Y. 10004
(212) 425-7200 (Telephone)
(212) 425-5288 (Facsimile)
CUSTOMER NO. 26646



**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
PTO-1449**

ATTY. DOCKET NO.
10793/70

SERIAL NO.
10/611,588

APPLICANT(S) **LEVANON, et al.**

FILING DATE
June 30, 2003

GROUP
1644

U. S. PATENT DOCUMENTS

EXAMINER INITIAL	PATENT NUMBER	PATENT DATE	INVENTORS NAME
	5,168,062	12/1/92	Stinski
	5,223,409	6/29/93	Ladner et al.
	5,385,839	1/31/95	Stinski
	5,403,484	4/4/95	Ladner et al.
	5,427,908	6/25/95	Dower et al.
	5,432,018	7/11/95	Dower et al.
	5,716,836	2/10/98	Suiko
	5,720,954	2/24/98	Hudziak et al.
	5,763,215	6/9/98	Blumberg et al.
	5,795,776	8/18/98	Fischer
	5,821,337	10/13/98	Carter et al.
	5,843,439	12/1/98	Anderson et al.
	5,945,304	8/31/99	Fischer
	6,132,730	10/17/00	Thorpe, et al.
	6,312,694	11/6/01	Thorpe et al.
	2002/0058034	5/16/02	Manjunath et al.

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
				YES	NO
	WO 94/26787	11/24/94	PCT		
	WO 00/29004	5/25/00	PCT		
	EP 0 589 877	11/13/96	Europe		

OTHER DOCUMENTS

EXAMINER INITIAL	AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.
	Adams et al., "Prolonged in vivo tumour retention of a human diabody targeting the extracellular domain of human HER2/neu," British Journal of Cancer (1998) Vol. 77, No. 9, pp. 1405-1412
	Afshar-Kharghan, et al., "Human polymorphism of P-selectin glycoprotein ligand 1 attributable to variable numbers of tandem decameric repeats in the mucinlike region," Blood, Vol. 97, No. 10, May 15, 2001, pp. 3306-3307
	Altman, et al., "Phenotypic Analysis of Antigen-Specific T Lymphocytes," Science, Vol. 274, October 4, 1996, pp. 94-96
	Altschul et al. "Gapped BLAST and PSI-BLAST: a new generation of protein database search programs", Nucleic Acids Research, 1997, vol. 25, no. 17, pp. 3389-3402
	Bass, et al. "Hormone Phage: An enrichment method for variant proteins with altered binding properties", Proteins: Structure, Function and Genetics, 1990 vol. 8, pp. 309-314
	Bundgaard, et al., "New Consensus Features for Tyrosine O-Sulfation Determined by Mutational Analysis," The Journal of Biological Chemistry, Vol. 272, No. 35, August 29, 1997, pp. 21700-21705
	Caron et al., "Murine and Humanized Constructs of Monoclonal Antibody M195 (Anti-CD33) for the therapy of acute myelogenous leukemia", Cancer Supplement, Feb. 1, 1994, vol. 73, no. 3, pp.1049-1056
	Caron et al., "A Phase 1B trial of humanized monoclonal antibody M195 (Anti-CD33) in myeloid leukemia: specific targeting without immunogenicity"
	Clezardin, et al., "Role of Platelet Membrane Glycoproteins Ib/Ix and IIb/IIIa, and of Platelet α -Granule Proteins in Platelet Aggregation Induced by Human Osteosarcoma Cells," Cancer Research, Vol. 53, October 1, 1993, pp. 4695-4700
	Cochran, et al., "The Relationship of MHC-Peptide Binding and T Cell Activation Probed Using Chemically Defined MHC Class II Oligomers," Immunity, Vol. 12, March 2000, pp. 241-250
	Cwirla et al., "Peptides on phage: a vast library of peptides for identifying ligands", Proc. Nat'l. Acad. Sci. USA, August 1990, vol. 87, pp. 6378-6382
	de Kruijff, et al., "Leucine Zipper Dimerized Bivalent and Bispecific scFv Antibodies from a Semi-synthetic Antibody Phage Display Library," The Journal of Biological Chemistry, Vol. 271, No. 13, March 29, 1996, pp. 7630-7634
	Devlin et al., "Random peptide libraries: a source of specific protein binding molecules", Science, vol 249, pp. 404-406
	Gasic, et al., "Antimetastatic Effects Associated with Platelet Reduction," Proc. Natl. Acad. Sci. USA, Vol. 61, 1968, pp. 46-52
	Gilbert, et al., "The LAC Operator is DNA," Proc. Natl. Acad. Sci. USA, Vol. 58, 1967, p. 2415-2421
	Griffiths et al., "Isolation of high affinity human antibodies directly from large synthetic repertoires," EMBO Journal, 1994, vol. 13, no. 14, pp. 3245-3260
	Harrison, et al., "Screening of Phage Antibody Libraries," Methods in Enzymology, Vol. 267, 1996, pp. 83-109
	Henkart, "Lymphocyte-mediated cytotoxicity: two pathways and multiple effector molecules", Immunity, August 1984, vol. 1, pp. 343-346
	Holliger et al., " "Diabodies": small bivalent and bispecific antibody fragments", Proc. Nat'l. Acad. Sci, USA, July 1993, vol. 90, pp. 6444-6448
	Hudson et al., "High avidity scFv multimers; diabodies and triabodies", Journal of Immun. Methods, 1999, vol. 231, pp. 177-189
	Hudson, et al., "Recombinant antibody constructs in cancer therapy," Current Opinion in Immunology, Vol. 11, 1999, pp. 548-557
	Huo, et al., "Adhesion molecules and atherogenesis," Acta Physiol Scand. 2001, Vol. 173, pp. 35-43
	Jarvik et al., "Epitope Tagging", Annu. Rev. Genet., 1998, vol. 32, pp. 601-618
	Jurcic, et al., "Targeted alpha-particle therapy for myeloid leukemias: A phase I trial of bismuth-213-HuM195 (anti-CD33)," Blood, 90(suppl.): 504a, 1997
	Jurcic, et al., ABSTRACT #2528, Blood, 1992 (10 Suppl. Part 1-2)
	Kamiyama, et al., "Inhibition of Human Platelet Glycoprotein IIb/IIIa Binding to Fibrinogen by Tumor Cell Membrane Proteins," Cancer Research, Vol. 53, January 15, 1993, pp. 221-223
	Kamiyama, et al., "Inhibition of platelet GPIIb/IIIa binding to fibrinogen by serum factors: Studies of circulating immune complexes and platelet antibodies in patients with hemophilia, immune thrombocytopenic purpura, human immunodeficiency virus - related immune thrombocytopenic purpura, and systemic lupus erythematosus," J. Lab Clin. Med., (1991) Vol. 117, No. 3, pp. 209-217

EXAMINER INITIAL		AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.
		Karparkin, et al., "Role of Adhesive Proteins in Platelet Tumor Interaction in Vitro and Metastasis Formation In Vivo," J. Clin. Invest., Vol. 81, April 1988, pp. 1012-1019
		Kehoe, et al., "Tyrosine sulfation: a modulator of extracellular protein-protein interactions," Chemistry & Biology, Vol. 7, No. 3, 2000, pp. R57-R61
		Kieffer, et al., "Expression of Platelet Glycoprotein Ib α in HEL Cells," The Journal of Biological Chemistry, Vol. 261, No. 34, December 5, 1986, pp. 15854- 15862
		Kipriyanov, et al., "Single-chain antibody streptavidin fusions; Tetrameric bifunctional scFv-complexes with biotin binding activity and enhanced affinity to antigen," Hum. Antibod. Hybridomas, Vol. 6, No. 3, 1995, pp. 93-101
		Kishimoto, et al. (eds.) Leucocyte Typing VI: Proceedings of the Sixth International Workshop and Conference held in Kobe, Japan, 10-14 November 1996, pp. 1218-1219
		Kortt et al., "Single-chain Fv fragments of anti-neuraminidase antibody NC10 containing five- and ten-residue linkers form dimers and with zero-residue linker a trimer", Protein Engineering, 1997, vol. 10, no. 4, pp. 423-433
		Kostelny, et al., "Formation of a Bispecific Antibody by the Use of Leucine Zippers," The Journal of Immunology, Vol. 148, No. 5, March 1, 1992, pp. 1547-1553
		Libby, "Atherosclerosis: The New View," Scientific American, May 2002, pp. 28-37
		Ma, et al., "Obligatory Requirement of Sulfation for P-Selectin Binding to Human Salivary Gland Carcinoma Acc-M Cells and Breast Carcinoma ZR-75-30 Cells," Journal of Immunology, 2002, Vol. 168, pp. 1690-1696.
		McCafferty et al., "Phage antibodies: filamentous phage displaying antibody variable domains", Nature, Dec. 6, 1990, vol. 348, pp. 552-554
		McGraw et al., "Characterization of murine and humanized anti-CD33, gelonin immunotoxins reactive against myeloid leukemias", Cancer Immunol. Immunotherapy, 1994, vol. 39, pp. 367-374
		Malmborg, et al., "BIAcore as a tool in antibody engineering," Journal of Immunological Methods, 1995, Vol. 183, pp. 7-13
		Marks, et al., "By-Passing Immunization Human Antibodies from V-gene Libraries Displayed on Phage", J Mol. Biol., Vol. 222, 1991, pp.581-597
		Michelson, et al., "Partial Characterization of a Binding Site For von Willebrand Factor on Glycocalicin," Blood, January 1986, Vol. 67, No. 1, pp. 19-26
		Moore, et al., "Identification of a Specific Glycoprotein Ligand for P-selectin (CD62) on Myeloid Cells," The Journal of Cell Biology, Vol. 118, No. 2, July 1992, pp. 445-456
		Myszka, "Improving biosensor analysis," J. Mol. Recognit., 1999, Vol. 12., pp. 279-284
		Nissim et al., "Antibody fragments from a 'single pot' phage display library as immunochemical reagents", EMBO Journal, 1994, vol. 13, no. 3, pp. 692-698
		Oleksowicz, et al., "Characterization of Tumor-Induced Platelet Aggregation: The Role of Immunorelated GPIb and GPIIb/IIIa Expression by MCF-7 Breast Cancer Cells," Thrombosis Research, Vol. 79, No. 3, 1995, pp. 261-274
		Power, et al., "Synthesis of high avidity antibody fragments (scFv multimers) for cancer imaging," Journal of Immunological Methods, Vol. 242, 2000, pp. 193-204
		Ramachandran, et al., "Dimerization of a selectin and its ligand stabilizes cell rolling and enhances tether strength in shear flow," Proc. Natl. Acad. Sci. USA, Vol. 98, No. 18, August 28, 2001, pp. 10166-10171
		Roberts, et al., "Lysogenic Induction," Lambda II, Cold Spring Harbor Laboratory, 1983, pp. 123-144
		Rodgers, et al., "Tyrosine Sulfation Enhances but is not Required for PSGL-1 Rolling Adhesion on P-Selectin," Biophysical Journal, Vol. 81, October 2001, pp. 2001-2009
		Schmidt, et al., "The Cytomegalovirus Enhancer: a Pan-Active Control Element in Transgenic Mice," Mol. Cell. Biol., Vol. 10, August 1990, pp. 4406-4411
		Scott et al., "Searching for peptide ligands with an epitope library", Science, July 27, 1990, vol. 249, pp. 386-390
		Sgouros et al. ABSTRACT #979, J. Nucl. Med. Vol. 38 (5 Suppl.)
		Shebuski, et al., "Role of Inflammatory Mediators in Thrombogenesis," JPET, 2002, Vol. 300, No. 3, pp. 729-735
		Sievers et al., ABSTRACT #2246, Blood, vol. 90 (10 Suppl. 1 Part 1)
		Smith, "Filamentous Fusion Phage: Novel expression vectors that displayed cloned antigens on the virion surface", Science, June 14, 1985, vol. 228, pp. 1315-1317
		Snapp, et al., "A Novel P-Selectin Glycoprotein Ligand-1 Monoclonal Antibody Recognizes an Epitope Within the Tyrosine Sulfate Motif of Human PSGL-1 and Blocks Recognition of Both P-and L-Selectin," Blood, Vol. 91, No. 1, January 1, 1998, pp. 154-164
		Squier, et al., "Cell-mediated cytotoxic mechanisms", Current Opinion in Immunology, 1994, vol. 6, pp. 447-452

EXAMINER INITIAL	AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.
	Sun et al., "Antitumour activity of a chimeric antibody against the leucocyte antigen CD48", Cancer Immunol. Immunotherapy, 2000, vol. 48, pp. 595-602
	Takebe, et al., "Sra Promoter: an efficient and versatile mammalian cDNA Expression System....", Molecular and Cellular Biology, Jan. 1988, vol. 8, no. 1, pp. 466-472
	Thompson, et al. "A fully human antibody neutralising biologically active human TGFβ2 for use in therapy", J. of Immunol. Methods, 1999, vol. 227, pp. 17-26
	Tomlinson, et al., The repertoire of human germline V _H segments with different hypervariable loops", J. Mol. Biol., 1992, vol. 227, pp. 776-798
	Tomlinson, "Complement defense mechanism," Current Opinion in Immunology, Vol. 5, 1993, pp. 83-89
	Varki, et al., "P-selectin, carcinoma metastasis and heparin: novel mechanistic connections with therapeutic implications," Braz. J. Med. Biol. Res., Vol. 34, No. 6, 2001, pp. 711-717
	Wang, et al., "Prevention of Intimal Hyperplasia With Recombinant Soluble P-Selectin Glycoprotein Ligand-Immunoglobulin in the Procine Coronary Artery Balloon Injury Model," JACC, August 2001, Vol. 38, No. 2, pp. 577-582
	Ward, et al., "Mocarhagin, a Novel Cobra Venom Metalloproteinase, Cleaves the Platelet von Willebrand Factor Receptor Glycoprotein Ibα. Identification of the Sulfated Tyrosine/Anionic Sequence Tyr-276-Glu-282 of Glycoprotein Ibα as a Binding Site for von Willebrand Factor and α-Thrombin," Biochemistry, Vol. 35, No. 15, 1996, pp. 4929-4938
	Wu, et al., "Anti-carcinoembryonic antigen (CEA) diabody for rapid tumor targeting and imaging," Tumor Targeting, Vol. 4, 1999, pp. 47-58

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	